Literature DB >> 20166442

Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers.

Yunxia Li1, Xuehua Jiang, Ke Lan, Qian Jiang.   

Abstract

The objective of this study was to determine and compare the plasma concentrations of rosuvastatin following single- and multiple-dose administration in Chinese volunteers. The study was of an open label, randomized, three-way cross-over design and was conducted in 12 subjects. Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin. The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively. Similar findings were obtained after multiple dosing. A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed. The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively. Small differences in gender are not considered clinically relevant, and dose adjustments based on gender are not anticipated. But the state of fed or fasting will affect the pharmacokinetic of rosuvastatin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20166442     DOI: 10.1007/BF03191177

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  4 in total

1.  Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.

Authors:  Ken-ichi Nezasa; Kazutaka Higaki; Tadahiko Matsumura; Kazuhiro Inazawa; Hiroshi Hasegawa; Masayuki Nakano; Masahiro Koike
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

2.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.

Authors:  Edmund Lee; Stephen Ryan; Bruce Birmingham; Julie Zalikowski; Ruth March; Helen Ambrose; Rachael Moore; Caroline Lee; Yusong Chen; Dennis Schneck
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

3.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.

Authors:  Dennis W Schneck; Bruce K Birmingham; Julie A Zalikowski; Patrick D Mitchell; Yi Wang; Paul D Martin; Kenneth C Lasseter; Colin D A Brown; Amy S Windass; Ali Raza
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

4.  No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.

Authors:  Paul D Martin; Aaron L Dane; Olise M Nwose; Dennis W Schneck; Mike J Warwick
Journal:  J Clin Pharmacol       Date:  2002-10       Impact factor: 3.126

  4 in total
  1 in total

1.  Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.

Authors:  Jieon Lee; Su-Jin Rhee; SeungHwan Lee; Kyung-Sang Yu
Journal:  Drug Des Devel Ther       Date:  2018-04-06       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.